Suppr超能文献

不同口服抗凝强度下机械心脏瓣膜置换患者凝血激活和反应性纤溶标志物的测定

Determination of markers of coagulation activation and reactive fibrinolysis in patients with mechanical heart valve prosthesis at different intensities of oral anticoagulation.

作者信息

van Wersch J W, van Mourik-Alderliesten C H, Coremans A

机构信息

Haematological Laboratory, De Weber Hospital, Heerlen, The Netherlands.

出版信息

Blood Coagul Fibrinolysis. 1992 Apr;3(2):183-6. doi: 10.1097/00001721-199204000-00007.

Abstract

In a group of 60 patients with mechanical heart valve prosthesis prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimer have been determined in order to assess the residual coagulation activation and the extent of the reactive fibrinolysis. The patients were divided into three subgroups of 20 patients each with different intensities of oral anticoagulation as indicated by International Normalized Ratio (INR) values in the ranges 4.8-3.6, 3.5-2.5 and 2.4-2.1. From the two markers of coagulation activation studied (prothrombin fragment 1 + 2 and thrombin-antithrombin III (TAT)) the prothrombin fragment 1 + 2 was dependent on the INR level in all groups, although the median values were still significantly beneath the lower limit of the reference range. The D-dimer concentrations were unexpectedly high with respect to the low coagulation activation levels, as indicated by the D-dimer/TAT and D-dimer/F 1 + 2 ratios. This demonstrates the enhanced presence of fibrin degradation products as a scarcely described side-effect of oral anticoagulation. The anticoagulant properties of fibrin degradation products might contribute partly to the in vivo haemorrhagic risk in high-intensity oral anticoagulation. These results show, inasmuch as the prothrombin fragment 1 + 2 is concerned, that from the laboratory point of view the residual thrombin activity is low enough to be adequate under the therapeutical regimen followed in this study. However, the question of the efficacy of anticoagulation intensities can only be finally answered by clinical trials.

摘要

在一组60例接受机械心脏瓣膜置换术的患者中,检测了凝血酶原片段1 + 2、凝血酶 - 抗凝血酶III复合物和D - 二聚体,以评估残余凝血激活情况和反应性纤维蛋白溶解的程度。患者被分为三个亚组,每组20例,根据国际标准化比值(INR)值显示不同强度的口服抗凝,INR值范围分别为4.8 - 3.6、3.5 - 2.5和2.4 - 2.1。在所研究的两种凝血激活标志物(凝血酶原片段1 + 2和凝血酶 - 抗凝血酶III(TAT))中,凝血酶原片段1 + 2在所有组中均依赖于INR水平,尽管中位数仍显著低于参考范围的下限。相对于低凝血激活水平,D - 二聚体浓度意外地高,如D - 二聚体/TAT和D - 二聚体/F 1 + 2比值所示。这表明纤维蛋白降解产物的存在增加,这是口服抗凝鲜为人知的副作用。纤维蛋白降解产物的抗凝特性可能部分导致高强度口服抗凝时的体内出血风险。就凝血酶原片段1 + 2而言,这些结果表明,从实验室角度来看,残余凝血酶活性足够低,在本研究遵循的治疗方案下是足够的。然而,抗凝强度的疗效问题最终只能通过临床试验来回答。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验